Department of Urology, Hanyang University Seoul Hospital, Seoul, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Investig Clin Urol. 2023 Jul;64(4):338-345. doi: 10.4111/icu.20230095.
We aimed to compare the mortality rate and the risk for progression to end-stage renal disease (ESRD) and cardiovascular disease (CVD) between patients who underwent surgery for localized renal cell carcinoma (RCC) and those with chronic kidney disease (CKD) without surgery by investigating the National Health Insurance Service.
The surgical group (CKD-S) included patients who underwent radical or partial nephrectomy for RCC from 2007 to 2009. Grades of surgical CKD were classified according to the estimated glomerular filtration rate (eGFR) measured at a health screening within 2 years after surgery. The nonsurgical group (CKD-M) was graded according to the eGFR in the 2009-2010 health screenings. We performed 1:5 propensity score matching for age, gender, diabetes, hypertension, Charlson comorbidity index, smoking, alcohol consumption, baseline eGFR, and body mass index.
A total of 8,698 patients (CKD-S, n=1,521; CKD-M, n=7,177) were analyzed. The CKD-M group was at higher risk for progression to ESRD (hazard ratio [HR] 1.90, 95% confidence interval [CI] 1.04-3.44, p=0.036) and CVD (HR 1.17, 95% CI 1.06-1.29, p=0.002) than the CKD-S group. In the group of patients with grade 3 disease or higher, the CKD-M group was at significantly higher risk for progression to ESRD (HR 2.21, 95% CI 1.47-3.31, p<0.001), CVD (HR 1.32, 95% CI 1.20-1.45, p<0.001), and overall mortality (HR 1.50, 95% CI 1.21-1.86, p<0.001).
The risk for progression to ESRD, CVD, or mortality in patients with CKD-S may be lower than in patients with CKD-M.
通过国家健康保险服务调查,比较接受局部肾细胞癌 (RCC) 手术治疗的患者与未接受手术治疗的慢性肾脏病 (CKD) 患者的死亡率和进展为终末期肾病 (ESRD) 和心血管疾病 (CVD) 的风险。
手术组 (CKD-S) 包括 2007 年至 2009 年接受根治性或部分肾切除术治疗 RCC 的患者。根据手术前 2 年内健康筛查时测量的估算肾小球滤过率 (eGFR) 对手术性 CKD 分级。非手术组 (CKD-M) 根据 2009-2010 年健康筛查时的 eGFR 分级。我们对年龄、性别、糖尿病、高血压、Charlson 合并症指数、吸烟、饮酒、基线 eGFR 和体重指数进行了 1:5 倾向评分匹配。
共分析了 8698 例患者 (CKD-S,n=1521; CKD-M,n=7177)。CKD-M 组发生 ESRD 进展的风险较高 (风险比 [HR] 1.90,95%置信区间 [CI] 1.04-3.44,p=0.036) 和 CVD (HR 1.17,95% CI 1.06-1.29,p=0.002) 比 CKD-S 组高。在疾病等级 3 或更高的患者中,CKD-M 组发生 ESRD 进展的风险显著更高 (HR 2.21,95% CI 1.47-3.31,p<0.001)、CVD (HR 1.32,95% CI 1.20-1.45,p<0.001) 和总死亡率 (HR 1.50,95% CI 1.21-1.86,p<0.001)。
CKD-S 患者进展为 ESRD、CVD 或死亡的风险可能低于 CKD-M 患者。